In contrast to the previous experiment started at 8 weeks of age to study tumor progression, the alterations in myeloid and T cell populations were accompanied by a significant decrease in IL-6 and IL-4 serum levels in OGP-treated mice (Fig. 5d). This evidence concerns the gene OVGP1 and neoplasm.